Renogen Adverse Reactions

Epoetin alpha is generally well tolerated. The following are the reported adverse reactions in Epoetin alpha therapy: Hypertension: The most frequent adverse effect observed in patients receiving Epoetin alpha for anemia of chronic renal failure is development or exacerbation of hypertension. The risk of hypertensive episodes is greatest in patients with chronic renal failure who have preexisting hypertension or a history of hypertensive disease, however up to 80% of patients with chronic renal failure have a history of hypertension.
Patients with extremely low baseline hematocrits (e.g. less than 22%) also may be at risk for the development of hypertension.
Hypertension, associated with a clinically important increase in hematocrit, has been reported rarely during Epoetin alpha therapy in cancer patients with chemotherapy-induced anemia.
Hematologic effects: An increased incidence of partial or complete clotting at the site of vascular access has been observed in renal dialysis patients receiving Epoetin alpha.
Nervous system effects: Seizures have been reported occasionally in patients receiving Epoetin alpha.
Renal and electrolyte effects: Predialysis increases in serum concentrations of potassium, blood urea nitrogen (BUN), creatinine, uric acid and phosphate have been reported with Epoetin alpha therapy, especially in patients with chronic electrolyte abnormalities.
Other reported adverse reactions: see Table 2.

Click on icon to see table/diagram/image